Cencora, Inc., headquartered in the United States, is a prominent player in the global pharmaceutical and life sciences industry. Founded in 2022, the company has quickly established itself as a leader in providing comprehensive supply chain solutions, clinical trial services, and logistics for biopharmaceutical products. With a strong operational presence across North America, Europe, and Asia, Cencora is dedicated to enhancing patient access to innovative therapies. Cencora's unique offerings include temperature-controlled logistics and tailored distribution services, ensuring the integrity of sensitive products throughout the supply chain. The company’s commitment to quality and efficiency has earned it a notable position in the market, recognised for its ability to streamline processes and reduce time-to-market for critical medications. As Cencora continues to grow, it remains focused on delivering exceptional value to its partners and clients in the ever-evolving healthcare landscape.
How does Cencora, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cencora, Inc.'s score of 42 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Cencora, Inc. reported total carbon emissions of approximately 135,087,000 kg CO2e for Scope 1, 88,699,000 kg CO2e for Scope 2 (market-based), and a significant 40,504,539,000 kg CO2e for Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, covering all relevant scopes. Cencora has set ambitious climate commitments, aiming for a 54.6% reduction in absolute Scope 1 and 2 greenhouse gas emissions by FY2032, using FY2019 as the baseline. Additionally, the company has pledged that 82% of its suppliers by spend will have science-based targets by FY2027. These targets align with the 1.5°C climate goal, demonstrating Cencora's commitment to sustainable practices within the healthcare sector. The company also aims to achieve net zero emissions by 2050 for both Scope 1 and Scope 2 emissions, further solidifying its long-term climate strategy. Cencora's initiatives reflect a proactive stance in addressing climate change and reducing its carbon footprint in the healthcare industry.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2024 | |
|---|---|---|---|
| Scope 1 | 98,742,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 110,191,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 19,881,916,000 | 00,000,000 | 00,000,000,000 |
Cencora, Inc.'s Scope 3 emissions, which increased significantly last year and increased by approximately 104% since 2019, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the primary emissions source at 1% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cencora, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Cencora, Inc.'s sustainability data and climate commitments